A cystectomy is the removal of the bladder and adjacent organs in patients with bladder
cancer. This often results in significant blood loss, and about 60% of patients will require
a blood transfusion during or up to 30 days after surgery. Significant blood loss may result
in cardiovascular morbidity, and the use of blood products are expensive and expose patients
to risk.
Tranexamic acid reduces breakdown of hemostatic blood clots and it has therapeutic benefit
when used in other surgical procedures to reduce blood loss and the need for transfusion. The
current study will be the first to evaluate whether tranexamic acid is effective and safe to
use during radical cystectomy. The results of the study will have an immediate impact on
patient care.